Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;83(1):1-36.
doi: 10.1007/s40265-022-01803-2. Epub 2022 Dec 12.

Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?

Alexia Plocque  1 , Christie Mitri  2 , Charlène Lefèvre  1 , Olivier Tabary  2 , Lhousseine Touqui  3   4   5 , Francois Philippart  6   7
Affiliations
Review

Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?

Alexia Plocque et al. Drugs. 2023 Jan.

Abstract

Severe manifestations of COVID-19 consist of acute respiratory distress syndrome due to an initially local reaction leading to a systemic inflammatory response that results in hypoxia. Many therapeutic approaches have been attempted to reduce the clinical consequences of an excessive immune response to viral infection. To date, systemic corticosteroid therapy is still the most effective intervention. More recently, new hope has emerged with the use of interleukin (IL)-6 receptor inhibitors (tocilizumab and sarilumab). However, the great heterogeneity of the methodology and results of published studies obfuscate the true value of this treatment, leading to a confusing synthesis in recent meta-analyses, and the persistence of doubts in terms of patient groups and the appropriate time to treat. Moreover, their effects on the anti-infectious or pro-healing response are still poorly studied. This review aims to clarify the potential role of IL-6 receptor inhibitors in the treatment of severe forms of COVID-19.

PubMed Disclaimer

Conflict of interest statement

AP, CM, CL, OT, LT, and FP have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

References

    1. Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2021;1:1-24. - PMC - PubMed
    1. Bradley BT, Bryan A. Emerging respiratory infections: The infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella. Semin Diagn Pathol. 2019;36:152–159. doi: 10.1053/j.semdp.2019.04.006. - DOI - PMC - PubMed
    1. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirol Carlton Vic. 2018;23:130–137. doi: 10.1111/resp.13196. - DOI - PMC - PubMed
    1. Vijayanand P, Wilkins E, Woodhead M. Severe acute respiratory syndrome (SARS): a review. Clin Med Lond Engl. 2004;4:152–160. doi: 10.7861/clinmedicine.4-2-152. - DOI - PMC - PubMed
    1. Fehr AR, Channappanavar R, Perlman S. Middle east respiratory syndrome: emergence of a pathogenic human coronavirus. Annu Rev Med. 2017;68:387–399. doi: 10.1146/annurev-med-051215-031152. - DOI - PMC - PubMed

Substances